HIV drug resistance is one of the major limitations in the successful treatment of HIV-infected patients using currently available antiretroviral combination therapies. When appropriate, drug susceptibility profiles should be taken into consideration in the choice of a specific combination therapy. Guidelines recommending resistance testing in certain circumstances have been issued. Many clinicians have access to resistance testing and will increasingly use these results in their treatment decisions. In this document, we comment on the different methods available, and the relevant issues relating to the clinical application of these tests. Specifically, the following recommendations can be made: (i) genotypic and phenotypic HIV-1 drug resistance analyses can yield complementary information for the clinician. However, insufficient information currently exists as to which approach is preferable in any particular clinical setting; (ii) when HIV-1 drug resistance testing is required, it is recommended that testing be performed on plasma samples obtained before starting, stopping or changing therapy, on samples that have a viral load above the detection limit of the resistance test; (iii) the panel recommends that genotypic and phenotypic HIV-1 drug resistance testing for clinical purposes be performed in a certified laboratory under strict quality control and quality assurance standards; and (iv) the panel recommends that resistance testing laboratories provide clinicians with resistance reports that include a list of drug-related resistance mutations (genotype) and/or a list of drug-related fold resistance values (phenotype), with interpretations of each by an experienced virologist. The interpretation of genotypic and phenotypic analysis is a complex and developing science, and in order to understand HIV-1 drug resistance reports, communication between the requesting clinician and the expert that interpreted the resistance report is recommended.
References
1.
MillerV., VandammeA-M, LovedayC., StaszewskiS., LundgrenJ., YouleM., Ait-KhaledM., BoucherC., Brun-VézinetF., DedesN., GiaquintoC., HertogsK., HouyezF., PerrinL., PillayD., SchmitJ-C, SchuurmanR., & LangeJ.M.Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting. AIDS2001; 15: 309–320.
2.
YouleM., HoltzerC., SimpsonK., de ClerqK., & MillerV.HIV-1 drug resistance testing: health outcomes issues. Antiviral Therapy2000; 5: 113–115.
3.
MillerV.European guidelines on resistance testing: why are they needed?HIV Medicine20001: 129–131.
4.
VandammeA-M, WitvrouwM., PannecouqueC., BalzariniJ., Van LaethemK., SchmitJ.C., DesmyterJ., & De ClercqE.Evaluating clinical isolates for their phenotypic and genotypic resistance against anti-HIV drugs. In Methods in Cellular and Molecular Medicine: Antiviral Chemotherapy Edited by KinchingtonD., & SchinaziR.F.1999; Totowa, NJ: The Humana Press Inc. pp. 223–258.
5.
StuyverL., WyseurA., RomboutA., LouwagieJ., ScarcezT., VerhofstedeC., RimlandD., SchinaziR.F., & RossauR.Line probe assay for rapid detection of drug-selected mutations in the human immunodeficiency virus type 1 reverse transcriptase gene. Antimicrobial Agents & Chemotherapy1997; 41: 284–291.
6.
LarderB.A., KellamP., & KempS.D.Zidovudine resistance predicted by direct detection of mutations in DNA from HIV-infected lymphocytes. AIDS1991; 5: 137–144.
7.
KayeS., LovedayC., & TedderR.S.A microtitre format point mutation assay: application to the detection of drug resistance in human immunodeficiency virus type-1 infected patients treated with zidovudine. Journal of Medical Virology1992; 37: 241–246.
8.
GünthardH.F., WongJ.K., IgnacioC.C., HavlirD.V., & RichmanD.D.Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV type 1 pol from clinical samples. AIDS Research and Human Retroviruses1998; 14: 869–876.
9.
RivaC., FontaineE., PeetersM., DelaporteE., SchmitJ-C, Van LaethemK., Van VaerenberghK., Van WijngaerdenE., De ClercqE., & VandammeA-MEvaluation of two commercial kits for testing genotypic drug resistance on a panel of HIV-1 clades A-J.2nd Frankfurt Symposium on the Clinical Implications of HIV Drug Resistance, Frankfurt, Germany, 25–27 February 2000.
10.
CollinG., DescampsD., TellesF., MatheronS., ObryV., CostagliolaD., & Brun-VézinetF.Differences in protease and reverse transcriptase sequences between the TruGene HIV-1 genotyping kit (Visible Genetics) and the ViroSeq genotyping system (PE Applied Biosystems). Antiviral Therapy2000; 5 (Suppl. 3): 53.
11.
WilsonJ.W., BeanP., RobinsT., GrazianoF., & PersingD.H.Comparative evaluation of three human immunodeficiency virus genotyping systems. Journal of Clinical Microbiology2000; 38: 3022–3028.
12.
ShaoX., EkstrandD.H.L., BhikhabhaiR., KallanderC.F., & GronowitzJ.S.A non-radioactive microtitre plate reverse transcriptase (RT) assay, based on immobilized template, for screening of RT activity inhibitors and evaluation of their mode of action. Antiviral Chemistry & Chemotherapy1997; 8: 149–159.
13.
Von der HelmK., SeelmeierS., KisselevA., & NitschkoH.Identification, purification and cell culture assays of retro-viral proteases. In Retroviral Proteases. Edited by KuoL.C., & ShaferJ.A.1994; 89–105. New York: Academic Press.
14.
KellamP., & LarderB.A.Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrobial Agents & Chemotherapy1994; 38: 23–30.
15.
MascheraB., FurfineE., & BlairE.D.Analysis of resistance to human immunodeficiency virus type 1 protease inhibitors by using matched bacterial expression and proviral infection vectors. Journal of Virology1995; 69: 5431–5436.
16.
HertogsK., de BéthuneM P., MillerV., IvensT., SchelP., Van CauwenbergeA., Van Den EyndeC., Van GerwenV., AzijnH., Van HoutteM., PeetersF., StaszewskiS., ConantM., BloorS., KempS., LarderB., & PauwelsR.A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrobial Agents & Chemotherapy1998; 42: 269–276.
17.
WalterH., SchmidtB., KornK., VandammeA-M, HarrerT., & UberlaK.Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. Journal of Clinical Virology1999; 13: 71–80.
18.
ParkinN.T., LieY.S., HellmannN., MarkowitzM., BonhoefferS., HoD.D., & PetropoulosC.J.Phenotypic changes in drug susceptibility associated with failure of human immunodeficiency virus type 1 (HIV-1) triple combination therapy. Journal of Infectious Diseases1999; 180: 865–870.
19.
ZennouV., MammanoF., PaulousS., MathezD., & ClavelF.Loss of viral fitness associated with multiple Gag and Gag-Pol processing defects in human immunodeficiency virus type 1 variants selected for resistance to protease inhibitors in vivo. Journal of Virology1998; 72: 3300–3306.
20.
QariS.H., RespessR., WeinstockH., BeltramiE., HertogsK., LarderB.A., PetropoulosC.J., HellmanN., & HeneineW.A comparative analysis of Virco Antivirogram and ViroLogic PhenoSense phenotypic assays for drug susceptibility of HIV-1. Antiviral Therapy2000; 5 (Suppl. 3): 49.
21.
Van LaethemK., Van VaerenberghK., SchmitJ-C, SprecherS., HermansP., De VroeyV., SchuurmanR., HarrerT., WitvrouwM., Van WijngaerdenE., StuyverL., Van RanstM., DesmyterJ., De ClercqE., & VandammeA-MPhenotypic assays and sequencing are less sensitive than point mutation assays for the detection of resistance in mixed HIV-1 genotypic populations. Journal of AIDS1999; 22: 107–118.
22.
VillahermosaM.L., ContrerasG., Péres-AlvarezL., BruF., MedranoL., DelgadoE., ColomoC., ThomsonM., & NajeraR.Evaluation of mixtures of wild-type HIV-1 and HIV-1 with resistance point mutations against reverse transcriptase inhibitors. Antiviral Therapy1998; 3: 221–228.
23.
ShaferR.W., WintersM.A., MayersD.L., JapourA.J., KuritzkesD.R., WeislowO.S., WhiteF., EriceA., SannerudK.J., IversenA., PenaF., DimitrovD., FrenkelL.M., & ReichelderferP.S.Interlaboratory comparison of sequence-specific PCR and ligase detection reaction to detect a human immunodeficiency virus type 1 drug resistance mutation. The AIDS Clinical Trials Group Virology Committee Drug Resistance Working Group. Journal of Clinical Microbiology1996; 34: 1849–1853.
24.
Puchhammer-StocklE., SchmiedB., MandlC.W., VetterN., & HeinzF.X.Comparison of line probe assay (LiPA) and sequence analysis for detection of HIV-1 drug resistance. Journal of Medical Virology1999; 57: 283–289.
25.
SchuurmanR., BrambillaD., de GrootT., & BoucherC.Second worldwide evaluation of HIV-1 drug resistance genotyping quality using the ENVA 2 panel. Antiviral Therapy1999: 4 (Suppl. 1): 41 (Abstr. 58).
26.
SchmitJ-C, RuizL., StuyverL., Van LaethemK., VanderlindenI., PuigT., RossauR., DesmyterJ., De ClercqE., ClotetB., & VandammeA-MComparison of the LiPA HIV-1 RT test, selective PCR and direct solid phase sequencing for the detection of HIV-1 drug resistance mutations. Journal of Virological Methods1998; 73: 77–82.
27.
PetropoulosC.J., ParkinN.T., LimoliK.L., LieY.S., WrinT., HuangW., TianH., SmithD., WinslowG.A., CaponD.J., & WhitcombJ.M.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy2000; 44: 920–928.
De BéthuneM-P, HertogsK., HeyndrickxJ., FransenK., AzijnH., MichielsL., JanssensW., ScholliersA., LarderB., BloorS., PauwelsR., & van der GroenG.Does natural or acquired resistance to reverse transcriptase and protease inhibitors, observed in HIV-1 groups M (subtypes A–H) and O, differ from subtype B?Antiviral Therapy1999: 4 (Suppl. 1): 33. (Abstr. 49.).
30.
VaheyM., NauM.E., BarrickS., CooleyJ.D., SawyerR., SleekerA.A., VickermanP., BloorS., LarderB., MichaelN.L., & WegnerS.A.Performance of the Affymetrix GeneChip HIV PRT 440 platform for antiretroviral drug resistance genotyping of human immunodeficiency virus type 1 clades and viral isolates with length polymorphisms. Journal of Clinical Microbiology1999; 37: 2533–2537.
31.
GünthardH F., WongJ.K., IgnacioC.C., GuatelliJ.C., RiggsN.L., HavlirD.V., & RichmanD.D.Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. Journal of Virology1998; 72: 2422–2428.
32.
KayeS., ComberE., TenantF.M., & LovedayC.The appearance of drug resistance-associated point mutations in HIV type 1 plasma RNA precedes their appearance in proviral DNA. AIDS Research and Human Retroviruses1995; 11: 1221–1225.
33.
EriceA., LiW., HenryK., & BalfourH.H.HIV drug resistance mutations in plasma closely represent viral sequences in lymphoid tissue. Antiviral Therapy1999; 4 (Suppl. 1): 48. (Abstr. 70.).
34.
HavlirD.V., & RichmanD.D.Viral dynamics of HIV: implications for drug development and therapeutic strategies. Annals of Internal Medicine1996; 124: 984–994.
35.
SharmaP.L., & CrumpackerC.S.Attenuated replication of human immunodeficiency virus type 1 with a didanosine-selected reverse transcriptase mutation. Journal of Virology1997; 71: 8846–8851.
36.
BoyerP.L., & HughesS.H.Analysis of mutations at position 184 in reverse transcriptase of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy1995; 39: 1624–1628.
37.
BackN.K., NijhuisM., KeulenW., BoucherC.A., Oude EssinkB.O., van KuilenburgA.B., van GennipA.H., & BerkhoutB.Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO Journal1996; 15: 4040–4049.
38.
UenoT., ShirasakaT., & MitsuyaH.Enzymatic characterization of human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 2’,3′-dideoxynucleoside 5′-triphosphates. Journal of Biological Chemistry1995; 270: 23605–23611.
39.
VerhofstedeC., Van WanzeeleF., Van Der GuchtB., De CabooterN., & PlumJ.Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS1999; 13: 2541–2546.
40.
DevereuxH.L.Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS1999; 13: F123–F127.
41.
DeeksS.G., WrinT., HohR., TroianoJ., LieglerT., HaydenM., PetropoulosC., HellmannN., BarbourJ., GrantR.M., McCuneJ.M., & HellersteinM.Virologic and immunologic evaluation of structured treatment interruptions (STI) in patients experiencing long-term virologic failure. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. LB10.
42.
AquaroS., CalioR., BalestraE., BagnarelliP., CenciA., BertoliA., TavazziB., Di PierroD., FrancesconiM., AbdelahadD., & PernoC F.Clinical implications of HIV dynamics and drug resistance in macrophages. Journal of Biological Regulators and Homeostatic Agents1998; 12: 23–27.
43.
EronJ.J., VernazzaP.L., JohnstonD.M., Seillier-MoiseiwitschF., AlcornT.M., FiscusS.A., & CohenM.S.Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: implications for transmission. AIDS1998; 12: F181–F189.
44.
De PasqualeM.P., RosenbergE., QuayleA., TremblayC., Martinez-PicadoJ., AllegaJ., SuttonL., ShiL., SavaraA.V., BoswellS., SaxP., HirschM., CaliendoA., AndersonD., WalkerB.D., & D'AquilaR.T.Primary HIV infection: in vivo fitness of pre-therapy resistant mutants and potential for secondary spread of HIV from semen. Antiviral Therapy1999; 4 (Suppl. 1): 89. (Abstr. 126.).
45.
KiesslingA.A., FitzgeraldL.M., ZhangD., ChayH., BrettlerD., EyreR.C., SteinbergJ., McGowanK., & ByrnR.A.Human immunodeficiency virus in semen arises from a genetically distinct virus reservoir. AIDS Research and Human Retroviruses1998; 14 (Suppl. 1): S33–S41.
46.
KashubaA.D., DyerJ.R., KramerL.M., RaaschR.H., EronJ.J., & CohenM.S.Antiretroviral-drug concentrations in semen: implications for sexual transmission of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy1999; 43: 1817–1826.
47.
StrappeP.M., BellJ.E., & SimmondsP.Persistence of drug-resistant variants of HIV-1 in the brain following combination therapy. AIDS Weekly1999; 15.
48.
Van VaerenberghK., Van LaethemK., AlbertJ., BoucherC.A., ClotetB., FloridaM., GerstoftJ., HeijdemanB., NielsenC., PannecouqueC., PerrinL., PirilloM.F., RuizL., SchmitJ-C, SchneiderF., SchoolmeesterA., SchuurmanR., StellbrinkH.J., StuyverL., Van LunzenJ., Van RemoortelB., Van WijngaerdenE., VellaS., WitvrouwM., YerlyS., De ClercqE., DesmyterJ., & VandammeA-MPrevalence and characteristics of multinucleoside-resistant HIV-1 among European patients receiving combinations of nucleoside analogues. Antimicrobial Agents & Chemotherapy2000; 44: 2109–2117.
49.
VandammeA-M, Van LaethemK., & De ClercqE.Managing resistance to anti-HIV drugs. An important consideration for effective disease management. Drugs1999; 57: 337–361.
50.
SchuurmanR., DemeterL., ReichelderferP., TijnagelJ., de GrootT., & BoucherC.Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase. Journal of Clinical Microbiology1999; 37: 2291–2296.
51.
HertogsK., ZolopaA., BloorS., ShaferB., De VroeyV., WarfordA., LarderB., & MeriganT.A blinded comparative analysis of two genotyping service laboratories: full sequence analysis of HIV-1 protease and reverse transcriptase. Antiviral Therapy1999; 4 (Suppl. 1): 59. (Abstr. 87.).
52.
HarriganP.R., VerbiestW., LarderB., HertogsK., TilleyJ., RaboudJ., & MontanerJ.Impact of moderate decreases in baseline NNRTI susceptibility on response to antiretroviral therapy. Antiviral Therapy2000; 5 (Suppl. 3): 68 (Abstr. 86).
53.
BachelerL., PloughmanL., HertogsK., & LarderB.Impact of baseline NNRTI resistance on the efficacy of efavirenz combination therapy in NNRTI therapy-naive patients (study DMP 266-006). Antiviral Therapy2000; 5 (Suppl. 3): 70 (Abstr. 88).
54.
MillerV., Cozzi LepriA., HertogsK., GuteP., LarderB., BloorS., KlaukeS., RabenauH., PhillipsA., & StaszewskiS.HIV drug susceptibility and treatment response to mega-HAART regimen in patients from the Frankfurt HIV cohort. Antiviral Therapy2000; 5: 49–55.
55.
HarriganP.R., HertogsK., VerbiestW., PauwelsR., LarderB., KempS., BloorS., YipB., HoggR., AlexanderC., & MontanerJ.S.Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community setting. AIDS1999; 13: 1863–1871.
56.
KempfD., BrunS., RodeR., IsaacsonJ., KingM., XuY., RealK., HsuA., GrannemanR., LieY., HellmannN., BernsteinB., & SunE.Identification of clinically relevant phenotypic and genotypic breakpoints for ABT-378/r in multiple PI-experienced, NNRTI-naive patients. Antiviral Therapy2000; 5 (Suppl. 3): 70 (Abstr. 89).
57.
CalvezV., CostagliolaD., DescampsD., MatheronS., SimonA., ValantinM-A, KatlamaC., & Brun-VézinetF.Resistance and viral response to stavudine/lamivudine combination in zidovudine, didanosine and zalcitabine experienced patients in the ALTIS 2 ANRS trial. Antiviral Therapy2000; 5 (Suppl. 3): 83 (Abstr. 107).
58.
SchinaziR.F., LarderB., & MellorsJ.W.Mutations in retro-viral genes associated with drug resistance: 2000–2001 update. International Antiviral News2000; 8: 65–91.
59.
Menéndez-AriasL., & DomingoE.Amino acid substitutions associated with resistance to HIV-1 reverse transcriptase and protease inhibitors. In Guide to management of HIV resistance and pharmacokinetics of drug therapy. Edited by ClotetB., Menénendez-AriasL., RuizL., TuralC., VandammeA-M, BurgerD., ShapiroJ.M., BoucherC.A., D'AquilaR., & RichmanD.D.2000; pp. 31–53. Barcelona, Spain: Editorial TAISA.
60.
ShaferR.W., KantorR., & GonzalesM.J.The genetic basis of HIV-1 resistance to reverse transcriptase and protease inhibitors. AIDS Reviews2000; 2: 211–228.
LarderB.A., KempS.D., & HertogsK.Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (Vitual Phenotype). Antiviral Therapy2000; 5 (Suppl. 3): 49 (Abstr. 63).
63.
StuyverL., VerhelstR., SchoolmeesterA., PottelH., SchmitJ., & RossauR.HIV-1 drug resistance testing: a key mutation concept. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, Calif., USA, 26–29 September 1999. Abstr. 421.
64.
SchmidtB., WalterH., MoschikB., PaatzC., Van VaerenberghK., VandammeA-M, SchmittM., HarrerT., HelmM., ÜberlaK., & KornK.Simple algorithm derived from a geno-/phenotypic database to predict HIV-1 protease inhibitor resistance. AIDS2000; 14: 1731–1738.
65.
Mendéndez-AriasL., & DomingoE.Sensitivity to reverse transcriptase and protease inhibitors of recombinant HIV clones harbouring resistance mutations: in vitro studies. In Guide to management of HIV resistance and pharmacokinetics of drug therapy. Edited by ClotetB., Menéndez-AriasL., RuizL., TuralC., VandammeA-M, BurgerD., ShapiroJ.M., BoucherC.A., D'AquilaR., & RichmanD.D.2000; pp. 55–84. Barcelona, Spain: Editorial TAISA, S.L.
66.
VandammeA-M. Possible genotypic and phenotypic algorithm for the clinical use of HIV-1 drug resistance testing. In Guide to management of HIV resistance and pharmacokinetics of drug therapy. Edited by ClotetB., Menéndez-AriasL., RuizL., TuralC., VandammeA-M, BurgerD., ShapiroJ.M., BoucherC.A., D'AquilaR., & RichmanD.D.2000; pp. 85–89. Barcelona, Spain: Editorial TAISA, S.L.
67.
TanuriA., VicenteA.C.P., OtsukiK., RamosC.A., FerreiraO.C., SchechterM., JaniniL.M., PieniazekD., & RayfieldM.A.Genetic variation and susceptibilities to protease inhibitors among subtype B and F isolates in Brazil. Antimicrobial Agents & Chemotherapy1999; 43: 253–258.
68.
PalmerS., AlaeusA., AlbertJ., & CoxS.Drug susceptibility of subtypes A, B, C, D and E human immunodeficiency virus type 1 primary isolates. AIDS Research and Human Retroviruses1998; 14: 157–162.
69.
ShaferR.W., ChuangT.K., HsuP., WhiteC.B., & KatzensteinD.A.Sequence and drug susceptibility of subtype C protease from human immunodeficiency virus type 1 seroconverters in Zimbabwe. AIDS Research and Human Retroviruses1999; 15: 65–69.
70.
VandammeA.M., DebyserZ., PauwelsR., De VreezeK., GoubauP., YouleM., GazzardB., StoffelsP.A., CauwenberghG.F., AnneJ., AndriesK., JanssenP.A.J., DesmyterJ., & De ClercqE.Characterization of HIV-1 strains isolated from patients treated with TIBO R82913. AIDS Research and Human Retroviruses1994; 10: 39–46.
71.
CoxS.W., ApériaK., AlbertJ., & WahrenB.Comparison of the sensitivities of primary isolates of HIV type 2 and HIV type 1 to antiviral drugs and drug combinations. AIDS Research and Human Retroviruses1994; 10: 1725–1729.
72.
ApetreiC., DescampsD., CollinG., Loussert-AjakaI., DamondF., DucaM., SimonF., & Brun-VézinetF.Human immunodeficiency virus type 1 subtype F reverse transcriptase sequence and drug susceptibility. Journal of Virology1998; 72: 3534–3538.
73.
DescampsD., CollinG., LetourneurF., ApetreiC., DamondF., Loussert-AjakaI., SimonF., SaragostiS., & Brun-VézinetF.Susceptibility of human immunodeficiency virus type 1 group 0 isolates to antiretroviral agents: in vitro phenotypic and genotypic analyses. Journal of Virology1997; 71: 8893–8898.
74.
St. ClairM.H., MartinJ.L., Tudor-WilliamsG., BachM.C., VavroC.L., KingD.M., KellamP., KempS.D., & LarderB.A.Resistance to ddI and sensitivity to AZT-induced by a mutation in HIV-1 reverse transcriptase. Science1991; 253: 1557–1559.
75.
DuewekeT.J., PushkarskayaT., PoppeS.M., SwaneyS.M., ZhaoJ.Q., ChenI.S.Y., StevensonM., & TarpleyW.G.A mutation in reverse transcriptase of bis(heteroaryl) piperazine-resistant human immunodeficiency virus type 1 that confers increased sensitivity to other nonnucleoside inhibitors. Proceedings of the National Academy of Sciences, USA1993; 90: 4713–4717.
76.
LarderB.A.3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to non-nucleoside reverse transcriptase inhibitors. Antimicrobial Agents & Chemotherapy1992; 36: 2664–2669.
77.
LarderB.A., KempS.D., & HarriganP.R.Potential mechanism for sustained antiretroviral efficacy of AZT-3TC combination therapy. Science1995; 269: 696–699.
78.
NijhuisM., SchuurmanR., de JongD., van LeeuwenR., LangeJ., DannerS., KeulenW., de GrootT., & BoucherC.A.Lamivudine-resistant human immunodeficiency virus type 1 variants (184V) require multiple amino acid changes to become co-resistant to zidovudine in vivo. Journal of Infectious Diseases1997; 176: 398–405.
79.
SchmitJ-C, Martinez-PicadoJ., RuizL., TuralC., Van LaethemK., CabreraC., IbanezA., PuigT., WitvrouwM., DesmyterJ., De ClercqE., ClotetB., & VandammeA-MEvolution of HIV drug resistance in zidovudine/zalcitabine-and zidovudine/didanosine-experienced patients receiving lamivudine-containing combination therapy. Antiviral Therapy1998; 3: 81–88.
80.
TachedjianG., MellorsJ., BazmiH., BirchC., & MillsJ.Zidovudine resistance is suppressed by mutations conferring resistance of human immunodeficiency virus type 1 to foscarnet. Journal of Virology1996; 70: 7171–7181.
81.
SchmitJ-C, CogniauxJ., HermansP., Van VaeckC., SprecherS., Van RemoortelB., WitvrouwM., BalzariniJ., DesmyterJ., De ClercqE., & VandammeA-MMultiple drug resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating human immunodeficiency virus type 1 patient strain. Journal of Infectious Diseases1996; 174: 962–968.
82.
WintersM.A., CoolleyK.L., GirardY.A., LeveeD.J., HamdanH., ShaferR.W., KatzensteinD.A., & MeriganT.C.A 6-base-pair insert in the reverse transcriptase gene of human immunodeficiency virus type 1 confers resistance to multiple nucleoside inhibitors. Journal of Clinical Investigation1998; 102: 1769–1775.
83.
BalzariniJ., KarlssonA., Pérez-PérezM-J, CamarasaM-J, TarpleyW.G., & De ClercqE.Treatment of human immunodeficiency virus type 1 (HIV-1)-infected cells with combinations of HIV-1-specific inhibitors results in a different resistance pattern than does treatment with single-drug therapy. Journal of Virology1993; 67: 5353–5359.
84.
BoyerP.L., LisziewiczJ., LoriF., & HughesS.H.Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. Journal of Molecular Biology1999; 286: 995–1008.
85.
De JongJ.J., GoudsmitJ., LukashovV., HillebrandM.E., BaanE., HuismansR., DannerS.A., ten VeenJ.H., de WolfF., & JurriaansS.Insertion of two amino acids combined with changes in reverse transcriptase containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs. AIDS1999; 13: 75–80.
86.
LarderB.A., BloorS., KempS.D., HertogsK., DesmetR.L., MillerV., SturmerM., StaszewskiS., RenJ., StammersD.K., StuartD.I., & PauwelsR.A family of insertion mutations between codons 67 and 70 of human immunodeficiency virus type 1 reverse transcriptase confer multinucleoside analog resistance. Antimicrobial Agents & Chemotherapy1999; 43: 1961–1967.
87.
IversenA.K., ShaferR.W., WehrlyK., WintersM.A., MullinsJ.I., ChesebroB., & MeriganT.C.Multidrug-resistant human immunodeficiency virus type 1 strains resulting from combination antiretroviral therapy. Journal of Virology1996; 70: 1086–1090.
88.
SchmitJ-C, Van LaethemK., RuizL., HermansP., SprecherS., SönnerborgA., LealM., HarrerT., ClotetB., ArendtV., LissenE., WitvrouwM., DesmyterJ., De ClercqE., & VandammeA-MMultiple dideoxynucleoside analogue-resistant (MddNR) HIV-1 strains isolated from patients from different European countries. AIDS1998; 12: 2007–2105.
89.
ShaferR.W., KozalM.J., WintersM.A., IversenA.K., KatzensteinD.A., RagniM.V., MeyerW.A., GuptaP., RasheedS., CoombsR., KatzmanM., FiscusS., & MeriganT.C.Combination therapy with zidovudine and didanosine selects for drug-resistant human immunodeficiency virus type 1 strains with unique patterns of pol gene mutations. Journal of Infectious Diseases1994; 169: 722–729.
90.
ShirasakaT., KavlickM.F., UenoT., GaoW.Y., KojimaE., AlcaideM.L., ChokekijchaiS., RoyB.M., ArnoldE., YarchoanR., & MitsuyaH.Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides. Proceedings of the National Academy of Sciences, USA1995; 92: 2398–2402.
91.
TamaletC., IzopetJ., KochN., FantiniJ., & YahiN.Stable rearrangements of the beta3-beta4 hairpin loop of HIV-1 reverse transcriptase in plasma viruses from patients receiving combination therapy. AIDS1998; 12: F161–F166.
92.
Van LaethemK., WitvrouwM., BalzariniJ., SchmitJ-C, SprecherS., HermansP., LealM., HarrerT., RuizL., ClotetB., Van RanstM., DesmyterJ., De ClerqE., & VandammeA-MPatient HIV-1 strains carrying the multiple nucleoside analogue resistance mutations are cross-resistant to abacavir. AIDS2000; 14: 469–471.
93.
FontaineE., Van VaerenberghK., VandammeA-M, & SchmitJ-CMultidrug-resistant human immunodeficiency virus type 1. AIDS Reviews2000; 1: 231–237.
94.
CalvezV., MourouxM., YvonA., DelaugerreC., BossiP., ValantinM.A., CoutellierA., BonmarchandM., HurauxJ-M, and KatlamaC.Zidovudine resistance associated mutations can be selected in patients after long-term exposure to stavudine. Antiviral Therapy1999; 4 (Suppl. 1): 26. (Abstr. 38.).
95.
de MendozaC., SorianoV., BrionesC., GallegoO., BarreiroP., AlvarezA., & Gonzalez LahozJ.Emergence of zidovudine resistance in HIV-infected patients receiving stavudine. Journal of Acquired Immune Deficiency Syndrome2000; 23: 279–81.
96.
KempS., BloorS., Van CauwenbergeA., De KoningI., Van den EyndeC., LarderB., & HertogsK.Analysis of 5000 HIV-1 clinical samples reveals complex non-nucleoside RT inhibitor resistance patterns. Antiviral Therapy1999; 4 (Suppl. 1): 20. (Abstr. 26.).
97.
LinP.F., GonzalezC.J., GriffithB., FriedlandG., CalvezV., FerchalF., SchinaziR. F., SheppD.H., AshrafA.B., WainbergM.A., SorianoV., MellorsJ.W., & ColonnoR.J.Stavudine resistance: an update on susceptibility following prolonged therapy. Antiviral Therapy1999; 4: 21–28.
98.
LorenziP., YerlyS., AbderrakimK., FathiM., RutschmannO.T., VonoverbeckJ., LeducD., PerrinL., HirschelB., BattegayM., BurgisserP., DoorlyR., EggerM., ErbP., FierzW., FleppM., FrancioliP., GrobP., GruningerU., LedergerberB., LuthyR., MalinverniR., MatterL., OpravilM., PaccaudF., PichlerW., RickenbachM., RuschmannO., & VernazzaP.Toxicity, efficacy, plasma drug concentrations and protease mutations in patients with advanced HIV infection treated with ritonavir plus saquinavir. AIDS1997; 11: F95–F99.
VenturiG., RomanoL., CatucciM., RiccioM.L., De MilitoA., GonnelliA., RubinoM., ValensinP.E., & ZazziM.Genotypic resistance to zidovudine as a predictor of failure of subsequent therapy with human immunodeficiency virus type-1 nucleoside reverse transcriptase inhibitors. European Journal of Clinical Microbiology and Infectious Diseases1999; 18: 274–282.
103.
ShaferR.W., WintersM.A., PalmerS., & MeriganT.C.Multiple concurrent reverse transcriptase and protease mutations and multidrug resistance of HIV-1 isolates from heavily treated patients. Annals of Internal Medicine1998; 128: 906–911.
104.
BoucherC.A., O'SullivanE., MulderJ.W., RamautarsingC., KellamP., DarbyG., LangeJ.M., GoudsmitJ., & LarderB.A.Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. Journal of Infectious Diseases1992; 165: 105–110.
105.
CaliendoA.M., SavaraA., AnD., DeVoreK., KaplanJ.C., & D'AquilaR.T.Effects of zidovudine-selected human immunodeficiency virus type 1 reverse transcriptase amino acid substitutions on processive DNA synthesis and viral replication. Journal of Virology1996; 70: 2146–2153.
106.
MollaA., KorneyevaM., GaoQ., VasavanondaS., SchipperP.J., MoH-M, MarkowitzM., ChernyavskiyT., NiuP., LyonsN., HsuA., GrannemanG.R., HoD.D., BoucherC.A.B., LeonardJ.M., NorbeckD.W., & KempfD.J.Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Medicine1996; 2: 760–766.
107.
NijhuisM., SchuurmanR., de JongD., EricksonJ., GustchinaE., AlbertJ., SchipperP., GulnickS., & BoucherC.A.Increased fitness of drug resistant HIV-1 protease as a result of acquisition of compensatory mutations during suboptimal therapy. AIDS1999; 13: 2349–2359.
108.
DeeksS.G., HellmannN.S., GrantR.M., ParkinN.T., PetropoulosC.J., BeckerM., SymondsW., ChesneyM., & VolberdingP.A.Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome. Journal of Infectious Diseases1999; 179: 1375–1381.
109.
DemeterL.M., DeGruttolaV., EshlemanS.H., JacksonJ.B., SquiresK., FischlM., HughesM., & HammerS.M.Baseline genotypic predictors of virological outcome in a clinical trial of indinavir plus zidovudine plus lamivudine (ACTG 320). Antiviral Therapy1999; 4 (Suppl. 1): 48 (Abstr. 69).
110.
Leigh BrownA.J., GünthardH.F., WongJ.K., D'AquilaR.T., JohnsonV.A., KuritzkesD.R., & RichmanD.D.Sequence clusters in human immunodeficiency virus type 1 reverse transcriptase are associated with subsequent virological response to antiretroviral therapy. Journal of Infectious Diseases1999; 180: 1043–1049.
111.
MeriganT.C., HirschR.L., FisherA.C., MeyersonL.A., GoldsteinG., & WintersM.A.The prognostic significance of serum viral load, codon 215 reverse transcriptase mutation and CD4+ T cells on progression of HIV disease in a double-blind study of thymopentin. AIDS1996; 10: 159–165.
112.
PikettyC., RaceE., CastielP., BelecL., PeytavinG., Si-MohamedA., Gonzalez-CanaliG., WeissL., ClavelF., & KazatchkineM.D.Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: phenotypic resistance to protease inhibitors predicts outcome of therapy. AIDS1999; 13: F71–F77.
113.
ReyD., HughesM., PiJ.T., WintersM., MeriganT.C., & KatzensteinD.A.HIV-1 reverse transcriptase codon 215 mutation in plasma RNA: immunologic and virologic responses to zidovudine. The AIDS Clinical Trials Group Study 175 Virology Team. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1998; 17: 203–208.
114.
Van VaerenberghK., Van LaethemK., Van WijngaerdenE., SchmitJ-C, SchneiderF., RuizL., ClotetB., VerhofstedeC., Van WanzeeleF., Muyldermans, SimonsP., StuyverL., HermansP., EvansC., De ClercqE., DesmyterJ., & VandammeA-MBaseline HIV Type-1 genotypic resistance to a newly added nucleoside analog is predictive for virologic failure of the new therapy. AIDS Research and Human Retroviruses2000; 16: 529–537.
115.
ZolopaA.R., ShaferR.W., WarfordA., MontoyaJ.G., KatzensteinD., & MeriganT.C.Predictors of antiviral response to saquinavir/ritonavir therapy in a clinical cohort who have failed prior protease inhibitors: a comparison of clinical characteristics, antiretroviral drug history and HIV genotype. Antiviral Therapy1998; 3 (Suppl. 1): 37.
116.
De GruttolaV., DixL., D'AquilaR., HolderD., PhillipsA., Ait-KhaledM., BaxterJ., ClevenberghP., HammerS., HarriganR., KatzensteinD., LanierR., MillerM., ParaM., YerlyS., ZolopaA., MurrayJ., PatickA., MillerV., CastilloS., PedneaultL., & MellorsJ.The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antiviral Therapy2000; 5: 41–48.
117.
KatzensteinT.L., JorgensonL.B., NielsenH., KirkO., SchuurmanR., NielsenC., & GerstoftJ.Lack of obvious interplay between baseline genotype and virological response among protease inhibitor-naive patients treated with HAART. Antiviral Therapy1999; 4 (Suppl. 1): 68 (Abstr. 104).
118.
KatlamaC., DuvivierC., MourouxM., LegrandM., ChiesaE., SchneiderL., Ait-MohandH., AgherR., CoutellierA., FievetM.H., RaceE., ClavelF., & CalvezV.GIGHAART: a rescue therapy for HIV patients with multiple HAART failures. Antiviral Therapy1999; 4 (Suppl. 1): 77 (Abstr. 113).
119.
KempfD., XuY., BrunS., KingM., MoH., RealK., BernsteinB., HertogsK., LarderB., MollaA., JapourA., & SunE.Baseline genotype and phenotype do not predict response to ABT-378/ritonavir in PI-experienced patients at 24 and 48 weeks. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 731.
120.
LanierE.R., MelbyT., St ClairM.H., ThorbornD., PearceG., HetheringtonS., SmileyL., & LafonS.Potential clinical impact of small differences between Virco antivirogram and ViroLogic phenosense assays for abacavir in 3TC experienced patients. 7th Conference on Retroviruses and Opportunistic Infections, San Francisco, Calif., USA, 30 January – 2 February 2000. Abstr. 788.
ClevenberghP., DurantJ., HalfonP., del GiudiceP., MondainV., MontagneN., SchapiroJ.M., BoucherC.A.B., & DellamonicaP.Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART: the Viradapt study, week 48 follow-up. Antiviral Therapy2000; 5: 65–70.
123.
BaxterJ.D., MayersD.L., WentworthD.N., NeatonJ.D., & MeriganT.C.Final results of CPCRA 046: a pilot study of antiretroviral management based on plasma genotypic anti-retroviral resistance testing (GART) in patients failing antiretroviral therapy. AIDS2000; 14: F83–F93.
124.
TuralC., RuizL., HoltzerC., VicianaP., González, FerrerE., Martínez-PicadoJ., RuizI., DalmauD., DomingoP., BeenA., BoucherC.A., SchapiroJ., RomeuJ., SireraG., ClotetB. & Havanna Study Group. The potential role of resistance decision support software with or without expert advice in a trial of HIV genotyping versus Standard of Care – the Havanna Trial. 40th Interdisciplinary Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 17–20 September 2000. Abstr. L-10.
125.
CohenC., KesslerH., HuntS., SensionM., FarthingC., ConantM., JacobsonS., NadlerJ., VerbiestW., HertogsK., AmesM., RinehartA., & GrahamN.Phenotypic resistance testing significantly improves response to therapy: final analysis of a randomized trial (VIRA 3001). Antiviral Therapy2000; 5 (Suppl. 3): 67.
126.
MeynardJ.L., VrayM., Morand-JoubertL., MatheronS., PeytavinG., ClavelF., Brun-VézinetF., & GirardP.M.Impact of treatment guided by phenotypic or genotypic resistance tests on the response to antiretroviral therapy: a randomized trial (NARVAL, ANRS 088). Antiviral Therapy2000; 5 (Suppl. 3): 67–68.
127.
WegnerS., GroenK., AronsonN., BarileA., EmmonsW., StephanK., TaskerS., StoffelsP., VerbiestW., PiotrovskyV., LarderB., & HertogsK.The potential role of resistance testing and therapeutic drug monitoring in the optimization of antiretroviral drug therapy. Antiviral Therapy1999; 4 (Suppl. 1): 77 (Abstr. 112).
128.
DescampsD., FlandreP., CalvezV., PeytavinG., MeiffredyV., CollinG., DelaugerreC., Robert-DelmasS., BazinB., AboulkerJ.P., PialouxG., RaffiF., & Brun-VézinetF.Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Journal of the American Medical Association2000; 283: 205–211.
129.
HavlirD.V., HellmannN.S., PetropoulosC.J., WhitcombJ.M., CollierA.C., HirschM.S., TebasP., SommadossiJ.P., & RichmanD.D.Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens. Journal of the American Medical Association2000; 283: 229–234.
130.
BalzariniJ., & De ClercqE.Biochemical pharmacology of nucleoside analogs active against HIV. In Textbook of AIDS Medicine. Edited by BroderS., MeriganT.C.Jr, & BolognesiD.1994; pp. 751–772. Baltimore: Williams & Wilkins.
131.
DianzaniF., AntonelliG., TurrizianiO., RivaE., SimeoniE., SignorettiC., StrosselliS., & CianfrigliaM.Zidovudine induces the expression of cellular resistance affecting its antiviral activity. AIDS Research and Human Retroviruses1994; 10: 1471–1478.
132.
SalomonH., GuZ., GaoQ., NagaiK., HiscottJ., & WainbergM.A.Host cell dependence of human immunodeficiency virus type-1 drug resistance profiles and tissue culture selection patterns. Antiviral Chemistry & Chemotherapy1995; 6: 222–229.
133.
MagnaniM., GazzanelliG., BrandiG., CasabiancaA., FraternaleA., ChiarantiniL., & RossiL.2’,3′-dideoxycytidine induced drug resistance in human cells. Life Sciences1995; 57: 881–887.
134.
PeterK., & GambertoglioJ.G.Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus. Clinical Pharmacology and Therapeutics1996; 60: 168–176.
135.
DurantJ., ClevenberghP., & GaraffoR.Importance of protease inhibitor levels in patients treated with genotypic adapted therapy: pharmacalogical data from the VIRADAPT study. AIDS2000; 14: 1333–1339.
HoetelmansR.M., ReijersM.H., WeverlingG.J., Ten KateR., WitF.W., MulderJ.W., WeigelH.M., FrissenP.H., RoosM., JurriaansS., SchuitemakerH., de WolfF., van BeijnenJH, & LangeJ.M.The effect of plasma drug concentrations on HIV-1 clearance rate during quadruple drug therapy. AIDS1998; 12: F111–F115.
138.
HirschM.S., Brun-VézinetF., D'AquilaR.T., HammerS., JohnsonV.A., KuritzkesD.R., LovedayC., MellorsJ.W., ClotetB., ConwayB., DemeterL.M., VellaS., JacobsonD.M., & RichmanD.D.Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society–USA panel. Journal of the American Medical Association2000; 283: 2417–2426.
139.
AntonE.D., & BachelorL.T.Development of HIV-1 genotypic resistance in patients failing efavirenz (EFV, DMP 266) plus nelfinavir (NFV) combination therapy [DMP 266–024]. 37th Annual Meeting of the Infectious Disease Society of America, Philadelphia, Pa., USA, 18–21 November 1999. Abstr. 320.
140.
BachelerL.T., AntonB., BakerD., BeckerM., LasutA., AujayM., BollingL., KrakowskiK., BunvilleJ., WangV., & AbremskiK.Genotypic correlates of in vivo resistance to efavirenz.6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 31 January – 4 February 1999. Abstr. 109.
141.
BoyerP.L., LisziewiczJ., LoriF., & HughesS.H.Analysis of amino insertion mutations in the fingers subdomain of HIV-1 reverse transcriptase. Journal of Molecular Biology1999; 286: 995–1008.
142.
CarrilloA., StewartK.D., ShamH.L., NorbeckD.W., KohlbrennerW.E., LeonardJ.M., KempfD.J., & MollaA.In vitro selection and characterization of human immunodeficiency virus type 1 variants with increased resistance to ABT-378, a novel protease inhibitor. Journal of Virology1998; 72: 7532–7541.
143.
DannerS.A., CarrA., LeonardJ.M., LehmanL.M., GudiolF., GonzalesJ., RaventosA., RubioR., BouzaE., PintadoV., AguadoA.G., De LomasJ.G., DelgadoR., BorleffsJ.C., HsuA., ValdesJ.M., BoucherC.A., & CooperD.A.A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. New England Journal of Medicine1995; 333: 1528–1533.
144.
DaveyR.J., ChaittD.G., ReedG.F., FreimuthW.W., HerpinB.R., MetcalfJ.A., EastmanP.S., FalloonJ., KovacsJ.A., PolisM.A., WalkerR.E., MasurH., BoyleJ., ColemanS., CoxS.R., WathenL., DaenzerC.L., & LaneH.C.Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents & Chemotherapy1996; 40: 1657–1664.
145.
De NoonD.J.AIDS Therapies.1998. Atlanta: Charles W Henderson.
146.
GülickR.M., MellorsJ.W., HavlirD., EronJ.J., GonzalezC., McMahonD., RichmanD.D., ValentineF.T., JonasL., MeibohmA., EminiE.A., & ChodakewitzJ.A.Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior anti-retroviral therapy. New England Journal of Medicine1997; 337: 734–739.
147.
KatzensteinD.A., HammerS.M., HughesM.D., GundackerH., JacksonJ.B., FiscusS., RasheedS., ElbeikT., ReichmanR., JapourA., MeriganT.C., & HirschM.S.The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. New England Journal of Medicine1996; 335: 1091–1098.
148.
LarderB., RichmanD., & VellaS.HIV resistance and implications for therapy.1998. Atlanta: Medicom Inc.
149.
LeaA.P., & FauldsD.Stavudine. A review of its pharmacodynamic and pharmacokinetic properties and clinical potential in HIV infection. Drugs1996; 51: 846–864.
150.
MarkowitzM., SaagM., PowderlyW.G., HurleyA.M., HsuA., ValdesJ.M., HenryD., SattlerF., La MarcaA., LeonardJ.M., & HoD.D.A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New England Journal of Medicine1995; 333: 1534–1539.
151.
PatickA.K., DuranM., CaoY., ShugartsD., KellerM.R., MazabelE., KnowlesM., ChapmanS., KuritzkesD.R., & MarkowitzM.Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir. Antimicrobial Agents & Chemotherapy1998; 42: 2637–2644.
152.
SchuurmanR., NijhuisM., van LeeuwenR., SchipperP., de JongD., CollisP., DannerS.A., MulderJ., LovedayC., & ChristophersonC.Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). Journal of Infectious Diseases1995; 171: 1411–1419.
153.
StaszewskiS., HarriganP.R., StoneC., GriffinP., TortellS., TisdaleM., & the CNAA 2002 International Project Group. Efficacy and resistance profile of abacavir at 24 and 48 weeks therapy including monotherapy and following switch to combination therapy (abacavir/zidovudine/ lamivudine). Antiviral Therapy1998; 3 (Suppl. 1): 68.
154.
TisdaleM., MyersR.E., Ait-KhaledM., & SnowdenW.HIV drug resistance analysis during clinical studies with the protease inhibitor amprenavir. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Ill., USA, 31 January – 4 February 1999. Abstr. 118.
155.
LanierE.R., ScottJ., SteelH., HetheringtonS., Ait-KhaledM., PearceG., SpreenW., & LafonS.Multivariate analysis of predictors of response to abacavir: comparison of prior antiretroviral therapy, baseline HIV RNA, CD4 count and viral resistance. Antiviral Therapy1999; 4 (Suppl. 1): 56 (Abstr. 82).
156.
HavlirD., CheesemanS.H., McLaughlinM.M., MurphyR., EriceA., SpectorS.A., GreenoughT.C., SullivanJ.L., HallD., MyersM., LamsonM., & RichmanD.D.High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. Journal of Infectious Diseases1995; 171: 537–545.
157.
HammondJ., CalefC., LarderB., SchinaziR., & MellorsJ.W.Mutations in retroviral genes associated with drug resistance. In Human Retroviruses and AIDS. Edited by KorberB., KuikenC., FoleyB., HahnB., McCutchanF., MellorsJ., & SodroskiJ.1998; pp. III-36 III-79. Los Alamos, N.M., USA: Theoretical Biology and Biophysics.
